Search Results

 

You need to login or register to view this content

All our reports and results are available free of charge personal use, and/or non-commercial use, however, you must first register with us to view our data.

View full Terms and Conditions



Log In

Respondent CDP 2009: Pfizer Inc.

General introduction
Pfizer Energy Climate Change ProgramFossil fuels like oil gas coal limited non renewable natural resource rely meet energy needs Scientific evidence continues support fact greenhouse gas (GHG) releases occur product fossil fuel combustion include carbon dioxide (CO2) emissions primary contributor global climate change environmental leader Pfizer public efforts decrease GHG emissions established public goals achieved significant GHG emission reductions energy efficiencies cost savings Pfizer corporate Energy Conservation Guideline 1996 internal energy climate change program 2000 seek reduce GHG emissions minimize cost operational restrictions arising carbon constrained environment assess risks operations adapt changes warming global climate recognized globally regionally locally commitment address challenging issues Climate Change Human Health Climate change happening experts believe adversely impacting global human health healthcare company commitment working healthier world Pfizer concerned health impacts According World Health Organization extreme weather flooding changes infectious disease patterns just ways climate change negatively affect health world particularly exclusively developing countries Industry governments public responsibility address evolving global health environmental challenge — Pfizer means continuing efforts reduce GHG emissions maintaining efforts infectious disease continuing commitment improving access medicines Public GoalsTo meet second generation GHG public goal reducing GHG emissions 20 percent absolute basis 2008 2012 (baseline 2007) achieve 35 percent electricity needs 2010 use cleaner energy technologies Commitments ActionsTo reduce GHG emissions 32 000 automobiles worldwide better understand scope 3 emissions contribution overall carbon footprint fulfill responsibilities Global Compact "Caring Climate Business Leadership Platform" effectively manage financial implications opportunities associated carbon constrained world identify operating risks business opportunities presented changing global climate END


Risk and Opportunities
1 Regulatory Risks (CDP6 1(a)(i))
1 1 company exposed regulatory risks related climate change
We consider our company to be exposed to regulatory risks. 
Europe Pfizer subject European Union Emission Trading Scheme (EU ETS) currently mandatory regulation applicable Pfizer operations Pfizer facilities Europe affected Phase ETS energy conservation efforts new entrant allowances Pfizer excess allocation facilities able provide facilities EU Pfizer did experience major direct impact Phase EU ETS Pfizer does anticipate Phase II major direct impact operations covered facilities power purchase operate Europe impacted costs allowances power generators required purchase Pfizer believes future regulations mandatory scheme include incentives businesses reduce energy use incentives facilities taken action reduce greenhouse gas (GHG) emissions current design EU ETS scheme example does provide credit early reduction emissions credit energy efficiency characteristics credit reductions indirect emissions act disincentive industry investment higher efficiency cogeneration demand opportunities example opportunity early action taken account use United States Environmental Protections Agency’ s (USEPA) Proposed Mandatory Greenhouse Gas Reporting Rule published Federal Register April 2009 Pfizer believes registry used ensure early actors given credit reductions GHG emissions future climate change legislation regulation United States Congress appears moving implementation climate change legislation Environmental Protection Agency moving regulation GHG Clean Air Act (CAA) details timing future legislation regulation carbon emissions United States uncertain emissions control area likely require regulated entities significantly reduce GHG emissions capital improvements purchase allowances offsets Additionally federal legislation regulation increase operating costs regulated unregulated entities past months USEPA making movements regulation GHG’ s Clean Air Act Advance Notice Proposed Rulemaking Regulating Greenhouse Gas Emissions Clean Air Act (ANPR) July 2008 Proposed Endangerment Cause Contribute Findings Greenhouse Gases Clean Air Act April 2009 Pfizer believes regulation GHGs CAA poses risk Company CAA framework does enable regulation GHGs way overly burdensome costly regulatory program does lend itself market based economically efficient control CAA drafted address air pollutants local regional effect evolved highly complex regulatory framework command control approach used implement CAA Example Regulation GHG pollutant Prevention Significant Deterioration (PSD) New Source Review (NSR) programs result number small pharmaceutical sales offices regulated Title V use small commercial boilers heating New comprehensive federal legislation provide incentives opportunities mitigate potentially harmful effects economy make real reductions GHG emissions way regulation CAA current form Additionally lack harmonization state requirements initiatives federal legislation regulation CAA pose additional burden facilities mandated comply potentially different requirements aimed achieving basically objective e reduction GHG emissions Pfizer preparing itself risks opportunities presented regulatory legislative developments taking steps reduce GHG emissions demonstrated achievement generation goal setting second generation public goal continuing look ways monetize energy efficiency renewable energy projects Additionally Pfizer’ s Global Energy Climate Change Team tracks salient legislative regulatory proposals applicable landmark court decisions subsequent regulatory directives Certain energy efficiency renewable energy incentives incorporated recent federal legislation (for example American Reinvestment Recovery Act 2009) offer opportunities future legislation regulation federal state levels mandatory scheme include additional targeted incentives businesses reduce energy use increase use renewable energy sources example Connecticut Clean Energy Fund fully funded Company unable pursue certain renewable energy projects state Pfizer’ s views risks opportunities presented changed substantially past months key difference CDP submission concern USEPA regulate GHGs CAA believe slow restrict growth present immediate cost implications Company

 
information

 
2 Physical Risks (CDP6 1(a)(ii))
2 1 company exposed physical risks climate change
We consider our company to be exposed to physical risks. 
pharmaceutical company develop manufacture product direct impact global climate change emit GHG emissions research manufacture transport sale Pfizer products market Pfizer sought minimize GHG emissions global company standard requiring conservation energy reduction greenhouse gases established 1996 Sea level rise frequent intense weather events potentially expose facilities supply chain physical risks flooding business interruption facility locations existing distribution networks believe risks significant near term Pfizer evaluated facilities believes physical risks stem climate change imminent example installed sea wall facility United Kingdom incorporated key design principles prevent flooding facility Singapore Lastly insurance group periodically reviews operations various natural disaster criteria related climate change including imminent flooding sea level rise increased likelihood hurricanes Pfizer’ s business model continues evolve expand (e g outsourcing key suppliers distribution centers) issues need consider potential impact climate change adverse weather patterns changing operations including stand facilities supply chain logistics related potential business interruption ability deliver medicines markets

 
information

 
3 Risks (CDP6 1(a)(iii))
3 1 company exposed risks result climate change
We consider our company to be exposed to other risks. 
EU ETS developed reduce GHG emissions Europe continues present risk higher costs energy Regulation GHG emissions increase energy costs measures implemented general commercial risks associated sale purchase carbon instruments CERs (FN1) EECs RECs especially voluntary market regulation regarding quality origin credits Recent information suggests viability Clean Development Mechanisms (CDMs) market value CERs tenuous factors (FN2) Relative general commercial risks associated transactions carbon markets evaluating investment energy efficiency projects purchase sale various carbon instruments Pfizer determined necessary look carefully project and/or instrument generated understand attributes offered project help achieve Pfizer’ s goal reducing emissions example determination credits generated project additional critical transfer title attributes represented instrument question determined necessary understand purchase sale entitles Pfizer reduce GHG emissions increase renewable energy consumption circumstances double counting reduction occur double counting avoided accounting actual emissions meeting voluntary goals Relative increasing energy costs Pfizer believes energy efficiency projects initiatives continue effective way manage energy costs reduce GHG emissions Pfizer believes renewable energy projects offer opportunities protect rising energy costs factor begun consider energy project financial review process Footnotes (FN) FN1 CERs Certified Emission Reductions = “ carbon credits” EECs Energy Efficiency Credits RECs Renewable Energy CreditsFN2 suggested considerably high rate error respect validation verification CERs specifically actual number CERs generated projects overestimated noted challenges regarding CERs include regulatory uncertainty regarding use past 2012 expiration date Kyoto Protocol limited price visibility substantial lead time project line register verify CERs

 
information

 
4 Regulatory Opportunities (CDP6 1(b)(i))
4 1 regulatory requirements climate change present opportunities company
Regulatory requirements present opportunities for my company. 
extent developing regulatory requirements early action account Pfizer positioned advantage credits incentives provided new regulatory frameworks based efforts reduce GHG emissions date including second generation GHG emissions reduction goals Pfizer recognizes energy conservation efficiency improvements offer significant cost savings opportunities monetize value GHG reductions turn used turn non financially viable energy efficiency clean energy projects financially viable projects various mandatory voluntary GHG markets developing worldwide present opportunities companies advantage value GHG reductions offer addition sale credits incentives available tax credits grants energy efficiency renewable energy projects Pfizer evaluates project scoping response question 1

 
information

 
5 Physical Opportunities (CDP6 1(b)(ii))
5 1 physical changes resulting climate change present opportunities company
Physical changes do not present opportunities for my company. 
pharmaceutical company develop manufacture product direct impact mitigation potential global climate change Based current understanding climate change anticipated physical changes result evaluating operating plans potential business opportunities

 
information

 
6 Opportunities (CDP6 1(b)(iii))
6 1 Does climate change present opportunities company
Climate change presents other opportunities for my company. 
potential adverse impact human health result climate change identified World Health Organization (WHO) particular notes increasingly significant human health impacts disproportionately occur developing countries access medicines quality public health care issues climate change impacts likely increase importance access medicines certain diseases Pfizer’ s continued commitment improving access medicines positive impact relative potential need response Question 1

 
information

 
Greenhouse Gas (GHG) Emissions Accounting, Emissions Intensity, Energy and Trading
7 Reporting Year (CDP6 Q2(a)(ii))
Information respond section “ Greenhouse Gas Protocol Corporate Accounting Reporting Standard (Revised Edition)” developed World Resources Institute World Business Council Sustainable Development (“ GHG Protocol” ) http //www ghgprotocol org/ ISO 14064 1 compatible GHG Protocol number regional/national programme protocols information http //www ghgprotocol org/ use guidance button provide CDP responses questions 7 8 9 10 1 10 2 11 1 11 2 years prior current reporting year time answered CDP information request work backwards current reporting year enter data oldest reporting period Questions 10 1 10 2 11 1 11 2 subsequent webpages dates answer question 7 carried forwards automatically populate webpages
7 1 state start date end date year reporting GHG emissions
Start date 01 January 2008End date 31 December 2008Financial accounting year 01 January 2008

 
8 Reporting Boundary (CDP6 Q2(a)(i)) 8 1 indicate category describes company entities group Scope 1 Scope 2 GHG emissions reported
Companies over which operational control is exercised. 

 
8 2 state parts business sources GHG emissions excluded reporting boundary
Pfizer’ s primary GHG emission CO2 combustion fossil fuels purchased electricity estimated contribution GHG emissions immaterial GHG footprint time materiality assessment based WRI GHG Protocol (A Corporate Accounting Reporting Standard) guidance 5% materiality threshold

 
9 Methodology (CDP6 Q2(a)(iii)) 9 1 process used company calculate Scope 1 Scope 2 GHG emissions including standard protocol methodology used collect activity data calculate Scope 1 Scope 2 GHG emissions provide answer text box addition description relevant select methodology list published methodologies aid automated analysis data
Pfizer follows WRI GHG Protocol salient parts WRI GHG Protocol requirements incorporated Pfizer’ s Inventory Management Plan (IMP) reviewed approved EPA’ s Climate Leaders program

 
Select methodologies
The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)


 
provide

 
9 2 Details assumptions
noted 8 2 Pfizer reports CO2 emissions resulting fossil fuel combustion purchased electricity GHG emissions immaterial footprint based WRI’ s 5% materiality threshold

 
9 3 names links calculation tools used
Pfizer uses Johnson Control Incorporated’ s tool calculating GHG emissions (i e JCI Energy & Emissions Management (E2MS))

 
Select calculation tools

 
9 4 global warming potentials applied origin
global warming potentials (GWP) Pfizer uses based WRI/WBCSD GHG Protocol calculation tool guidance Version 4 0 (Feb 2009) Substance GWPCH4 21CO2 1N20 310

 
9 5 emission factors applied origin
electricity emissions factors Pfizer uses U S facilities E GRID factors EPA issues updates International electricity factors taken GHG Protocol Calculation Tools Version 3 0 (March 2008) references International Energy Agency recent data available U S international electricity emissions factors 2005 emissions factors fuels including stationary fuels mobile fuels reference EPA’ s Climate Leaders GHG Inventory Protocol Core Module Guidance based WRI GHG Protocol supplier GHG inventory software maintains emissions factors service agreement

 
information
Pfizer provided data previous years

 
10 Scope 1 Direct GHG Emissions (CDP6 Q2(b)(i))
Instructions question 10 question 11 (following page)When providing answers questions 10 11 deduct offset credits Renewable Energy Certificates net estimated avoided emissions export renewable energy carbon sequestration (including enhanced oil recovery) use goods services Opportunities provide details activities reduce avoid emissions provided information request Carbon dioxide emissions biologically sequestered carbon e g carbon dioxide burning biomass/biofuels reported separately emissions Scopes 1 2 3 relevant report emissions question 15 include nitrous oxide methane emissions biomass/biofuel combustion emissions scopes
answer following questions using Table 1 provide 10 1 Total gross global Scope 1 GHG emissions metric tonnes CO2 ePlease break total gross global Scope 1 emissions 10 2 Country regionPlease provide CDP responses questions 10 1 10 2 years prior current reporting year time answered CDP information request work backwards current reporting year enter data oldest reporting period Table 1 (below) table 5 (Q11 1 11 2) automatically populated dates answer 7 1 Electric utilities report emissions country/region using table question EU3 Table 1 use numbers Use “ Other” option drop menu enter region
Reporting year Q7.1 Start date 01/01/2008
Reporting year Q7.1 End date 31/12/2008
10.1 Total gross global Scope 1 GHG
emissions in metric tonnes CO2-e
1017810

10.2 Gross Scope 1 emissions in metric tonnes CO2-e by country or region

Africa Middle East 10673
Americas 48276
Asia 100211
Europe 255403
USA 603244

 
answer question 10 1 automatically carried forward tables 2 3 add country region answer 10 2 press “ Save” end page tick box total gross global Scope 1 figure (Q10 1) includes emissions transferred outside reporting boundary (as given answer 8 1) report transfers 13 5

 
facilitate better understanding business break total global Scope 1 emissions 10 3 Business divisionand/or10 4 Facility10 3 Business division (only data current reporting year requested)Table 2 use numbers
Business Divisions - Enter names below
Scope 1 Metric tonnes CO2-e
Total gross global Scope 1 GHG emissions in metric tonnes CO2-e - answer to question Q10.1 1017810
Manufacturing 459236
Office 62594
Research Development 252746
Fleet 243230

 
10 4 Facility (only data current reporting year requested)Table 3 use numbers
Facilities - Enter names below
Scope 1 Metric tonnes CO2-e
Total gross global Scope 1 GHG emissions in metric tonnes CO2-e - answer to question Q10.1 1017810

 
10 5 break total global Scope 1 GHG emissions metric tonnes gas metric tonnes CO2 e GHG type (Only data current reporting year requested )Table 4 use numbers
Scope 1 GHG Type
Unit
Quantity
CO2 Metric tonnes 968727
CH4 Metric tonnes
CH4 Metric tonnes CO2-e
N2O Metric tonnes
N2O Metric tonnes CO2-e
HFCs Metric tonnes
HFCs Metric tonnes CO2-e 49080
PFCs Metric tonnes
PFCs Metric tonnes CO2-e
SF6 Metric tonnes
SF6 Metric tonnes CO2-e

 
10 6 provided information Scope 1 emissions response questions explain reasons plans collecting Scope 1 GHG emissions information future
applicable

 
information
Question 10 2 Pfizer specific regions aligned Business Units Markets Question 10 4 providing data facility given believe business breakdown provided Question 10 3 appropriate operations

 
11 Scope 2 Indirect GHG Emissions (CDP6 Q2(b)(i))
Important note emission factors zero low carbon electricity purchased emissions factor use calculating Scope 2 emissions depends electricity purchase counted calculating grid average emissions factor – supplier Electricity counted calculating grid average emissions factor electricity sourced grid electricity counted calculating grid average emissions factor Scope 2 emissions calculated using grid average emissions factor company purchases electricity zero low carbon electricity tariff Electricity counted calculating grid average emissions factor zero low carbon electricity sourced grid transmitted company electricity counted calculating grid average emissions factor specific method generation used provided certificates quantifying GHG related environmental benefits claimed electricity sold passed separately electricity purchased Click instructions previous page answering question 11
answer following questions using Table 5 provide 11 1 Total gross global Scope 2 GHG emissions metric tonnes CO2 e break total gross global Scope 2 emissions 11 2 Country regionPlease provide CDP responses questions 11 1 11 2 years prior current reporting year time answered CDP information request work backwards current reporting year enter data oldest reporting period Table 5 automatically populated dates gave answer 7 1 Table 5 use numbers Use “ Other” option drop menu enter region
Reporting year Q7.1 Start date 01/01/2008
Reporting year Q7.1 End date 31/12/2008
11.1 Total gross global Scope 2 GHG
emissions in metric tonnes CO2-e
1000959

11.2 Gross Scope 2 emissions in metric tonnes CO2-e by country or region

Africa Middle East 3234
Americas 24741
Asia 124583
Europe 151765
USA 696636

 
answer 11 1 automatically carried forward tables 6 7 add country region answer 11 2 press “ Save” end page facilitate better understanding business break total global Scope 2 emissions 11 3 Business divisionand/or11 4 Facility11 3 Business division (only data current reporting year requested)Table 6 use numbers
Business Divisions - Enter names below
Scope 2 Metric tonnes CO2-e
Total gross global Scope 2 GHG emissions in metric tonnes CO2-e - answer to question Q11.1 1000959
Manufacturing 748379
Office 48127
Research Development 204453

 
11 4 Facility (only data current reporting year requested)Table 7 use numbers
Facilities - Enter names below
Scope 2 Metric tonnes CO2-e
Total gross global Scope 2 GHG emissions in metric tonnes CO2-e - answer to question Q11.1 1000959

 
11 5 provided information Scope 2 emissions response questions explain reasons plans collecting Scope 2 GHG emissions information future

 
information
Question 11 2 Pfizer specific regions aligned Business Units Markets Question 11 3 scope 2 emissions Fleet Division Question 11 4 providing data facility given believe business breakdown provided Question 11 3 appropriate operations

 
12 Contractual Arrangements Supporting Particular Types Electricity Generation (CDP6 Q2(b)(i) Guidance)
12 1 consider grid average factor used report Scope 2 emissions question 11 does reflect contractual arrangements electricity suppliers (for example purchase electricity using zero low carbon electricity tariff) calculate report contractual Scope 2 figure response question showing origin alternative emission factor information tariff
Pfizer does purchase electricity using zero low carbon electricity tariff

 
12 2 retire certificates (eg Renewable Energy Certificates) associated zero low carbon electricity provide details
question applicable based response Question 12 1

 
information

 
13 Scope 3 Indirect GHG Emissions (CDP6 Q2(c))
following categories main sources emissions Report emissions metric tonnes CO2 e state methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions Notes question 13When providing answers question 13 deduct offset credits Renewable Energy Certificates net estimated avoided emissions export renewable energy carbon sequestration (including enhanced oil recovery) use goods services Opportunities provide details activities reduce avoid emissions provided information request Carbon dioxide emissions biologically sequestered carbon e g carbon dioxide burning biomass/biofuels reported separately emissions Scopes 1 2 3 relevant report emissions question 15 include nitrous oxide methane emissions biomass/biofuel combustion emissions scopes
13 1 Employee business travelDescribe main sources emissions
2004 did preliminary estimate Scope 3 emissions business travel estimate included colleague travel air rail car rentals commuting time estimated emissions business travel material GHG footprint based WRI materiality threshold 5% 2008 estimated emissions air travel component business travel 120 820 MT CO2 eq approximately 6% total GHG emissions 2008 light business travel emissions comprising large percentage emissions evaluate ways influence emissions consider inclusion emissions GHG footprint

 
Emissions metric tonnes CO2 e
120 820 MT CO2 eq

 
State methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions
Information provided requestor

 
13 2 External distribution/logisticsDescribe main sources emissions
respect external distribution logistics operations Pfizer joined EPA’ s Smartway Program Transport Partner February 2009 Puerto Rico operations Pfizer fulfilled SmartWay entry requirements present Pfizer uses tonnage reporting metric acceptable metric reporting SmartWay progress using tonnage metric does allow Pfizer generate emissions associated shipping products using mileage carriers Pfizer does currently track Pfizer plans capture mileage data associated carriers future begin tracking emissions logistics operations

 
Emissions metric tonnes CO2 e
present Pfizer uses tonnage reporting metric acceptable metric reporting SmartWay progress using tonnage metric does allow Pfizer generate emissions associated shipping products using mileage carriers Pfizer does currently track Pfizer plans capture mileage data associated carriers future begin tracking emissions logistics operations

 
State methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions
present Pfizer uses tonnage reporting metric acceptable metric reporting SmartWay progress using tonnage metric does allow Pfizer generate emissions associated shipping products using mileage carriers Pfizer does currently track Pfizer plans capture mileage data associated carriers future begin tracking emissions logistics operations

 
13 3 Use/disposal company’ s products servicesFor auto manufacture auto component companies – refer additional questions sectors completing question 13 3 main sources emissions
believe Scope 3 emissions disposal Company’ s products insignificant determined evaluation estimate

 
Emissions metric tonnes CO2 e
Information determined

 
State methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions
Information determined

 
13 4 Company supply chainDescribe main sources emissions
Pfizer continues evaluate Scope 3 emissions seek opportunities influence emissions area example completed preliminary GHG emissions calculations Scope 3 emissions manufacture pharmaceutical materials parties Based preliminary calculations soliciting energy usage information key pharmaceutical material suppliers better refine estimates addition held training sessions early 2009 selected contract manufacturing partners educate methods reduce energy consumption reducing GHG emissions

 
Emissions metric tonnes CO2 e
Information determined

 
State methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions
Information determined

 
13 5 OtherIf reporting emissions fall categories categorise transferred emissions non transferred emissions (please guidance explanation terms) report transfers input fields non transfers input fields TransfersDescribe main sources emissions
Applicable

 
TransfersReport emissions metric tonnes CO2 e
Applicable

 
TransfersState methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions
Applicable

 
Non transfersDescribe main sources emissions
Applicable

 
Non transfersReport emissions metric tonnes CO2 e
Applicable

 
Non transfersState methodology assumptions calculation tools databases emission factors (including sources) global warming potentials (including sources) used calculating emissions
Applicable

 
13 6 provided information categories Scope 3 GHG emissions response questions explain reasons plans collecting Scope 3 indirect emissions information future
Applicable

 
information

 
14 Emissions Avoided Use Goods Services (New CDP 2009)
14 1 goods and/or services enable GHG emissions avoided party provide details including estimated avoided emissions anticipated timescale emissions avoided methodology assumptions emission factors (including sources) global warming potentials (including sources) used estimations
question applicable goods services

 
information

 
15 Carbon Dioxide Emissions Biologically Sequestered Carbon (New CDP 2009)
example carbon dioxide burning biomass/biofuels

 
15 1 provide total global carbon dioxide emissions metric tonnes CO2 biologically sequestered carbon Emissions metric tonnes CO2 use numbers
0

 
information
Pfizer did generate CO2 emissions biologically sequestered carbon 2008

 
16 Emissions Intensity (CDP6 Q3(b))
16 1 supply financial emissions intensity measurement reporting year combined Scope 1 2 emissions measurement
Revenue (Million US$) 48 296

 
16 1 1 units example units metric tonnes CO2 e million Yen turnover metric tonnes CO2 e US$ profit metric tonnes CO2 e thousand Euros turnover
Total Emissions (tCO2eq) 2 018 769

 
16 1 2 resulting figure Use decimal point necessary use “ ” “ ” e write 15 6 15 6
41.8

 
16 2 supply activity related intensity measurement reporting year combined Scope 1 2 emissions measurement
Given scope Pfizer’ s operations differences associated bulk active pharmaceutical ingredient manufacturing final drug product manufacturing Pfizer does believe activity related intensity measurement appropriate operations

 
16 2 1 units e g metric tonnes CO2 e metric tonne output service sector businesses unit service provided
operations believe activity based intensity measurement illustrative emissions financial based measurement providing Question 16 1

 
16 2 2 resulting figure Use decimal point necessary use “ ” “ ” e write 15 6 15 6

 
information

 
17 Emissions History (CDP6 Q2(f))
17 1 emissions reporting year vary significantly compared previous years
Yes 
Pfizer continuing reduce GHG emissions 2007 data illustrates met goal reducing GHG emissions 35% million dollars revenue 2000 baseline achieving 43% reduction million dollars revenue downward trend GHG emissions result efficiency improvements gained consolidation certain operations energy conservation program consisting projects improve energy efficiency facilities global effort raise colleague awareness topics energy conservation climate change 2008 Pfizer achieved absolute energy reduction approximately 6% GHG emissions reduction 8% (equivalent 180 523 tCO2e) previous reporting period Similarly previous years GHG emissions reduction result consolidation certain operations energy conservation program consisting projects improve energy efficiency facilities raise colleague awareness topics energy conservation climate change

 
answer 17 1 Yes 17 1 1 Estimate percentage emissions vary compared previous reporting year box accept numerical answers containing decimal point use " " " " e write 10 6 10 6
8 %

 
emissions increased decreased
Decreased 

 
information

 
18 External Verification/Assurance (CDP6 Q2(d))
18 1 information reported response questions 10 – 15 externally verified/assured
None of the information provided in response to question 10-15 has been externally verified/assured in whole or in part. Please go to question 18.6. 

 
aid automated analysis responses select responses tick boxes use text box provided tick boxes menu options appropriate

 
18 2 State scope/boundary emissions included verification/assurance exercise

 
use text box scope/boundary emissions included verification/assurance exercise tick box menu options applicable

 
18 3 State level assurance (eg reasonable limited) given

 
18 4 Provide copy verification/assurance statement attach copy/copies

 
18 5 Specify standard information verified/assured

 
18 6 information provided response questions 10 15 verified state plans GHG emissions accounting information externally verified/assured future
GHG emission inventory methodology approved USEPA Climate Leaders Program preparation GHG emission inventory supported experienced energy consultant Currently exception facilities covered EU ETS Pfizer does externally verify audit GHG emissions inventory party considering option going forward EPA’ s Climate Leaders program continually reviews emissions inventory data progress reaching GHG emissions goal addition Pfizer received technical assistance EPA determining organizational operational boundaries identifying appropriate emission factors operations documenting decisions Inventory Management Plan (IMP) ensure consistency transparency inventory time EPA performs desktop reviews inventory data IMP ensure meet EPA's quality standards conducts risk based site IMP review ensure Management Plan implemented facility level reviews provide assurance EPA implemented GHG data collection management place track progress GHG reduction goal result EPA recognition corporate leadership climate change issue 2008 used team colleagues Global Energy Climate Change Team including representatives EHS engineering groups party consultant (who maintains actual database) assure energy usage emissions data integrity Pfizer member USEPA Climate Leaders program member Climate Leaders partnership minimum Pfizer required (1) Set aggressive corporate wide greenhouse gas (GHG) emissions reduction goal achieved 10 years (2) Perform corporate wide inventory major greenhouse gases (CO2 CH4 N2O HFCs PFCs SF6) completed building inventory step calculating mission reduction goal data collected quality assured external consultant inventory revealed CO2 principal GHG (3) Report annually inventory data USEPA document progress reduction goal USEPA independently verifies data report program participants measures progress achieving reduction target reporting obligations accordance WRI GHG Protocol USEPA Climate Leaders requirements requirements captured Pfizer’ s Inventory Management Plan Pfizer’ s written procedure collecting reporting GHG emissions information Climate Leaders partnership website www epa gov/climateleaders

 
information

 
19 Data Accuracy (CDP6 Q2(e) – New wording CDP 2009)
19 1 main sources uncertainty data gathering handling calculations e g data gaps assumptions extrapolation metering/measurement inaccuracies gather emissions data select emissions data gathered proceed question 20
Emission data is gathered. 
GHG emissions data based fuel invoices fuel electricity suppliers invoice payment process sites review invoices accuracy available data facility meters event fuel electricity suppliers adjust invoices initial issuance invoices retrospectively adjust usage amounts GHG inventory database

 
19 2 uncertainties affect accuracy reported data percentage terms estimated standard deviation
expect minor fluctuations invoice data materially affect reported data given relatively tight accuracy reported data EU ETS (See Q19 3 2) think fluctuations occur EU data materially affect data

 
19 3 Does company report GHG emissions mandatory voluntary scheme (other CDP) requires accuracy assessment
Yes (Please answer the following questions - 19.3.1, 19.3.2). 

 
19 3 1 provide scheme
EU emissions trading scheme 

 
19 3 2 provide accuracy assessment GHG emissions reported scheme report delivered
facilities Europe annually report data EU Emissions Trading Scheme (ETS) ETS requires data party verified submittal designated agencies accuracy assessment affected facilities recent report varies plus minus 1 percent plus minus 2 73 percent

 
information

 
20 Energy Fuel Requirements Costs (New CDP 2009)
provide following information reporting year Cost purchased energy
20 1 total cost electricity heat steam cooling purchased company
203526681

 
Select currency
United States dollar

 
20 1 1 break costs individual energy type Table 8 “ Cost” column accept text use numbers
Energy type
Cost
Currency
 Electricity 196364576 United States dollar
 Heat United States dollar
 Steam 6884817 United States dollar
 Cooling United States dollar

 
Cost purchased fuel20 2 total cost fuel purchased company mobile stationary combustion
202326158

 
Select currency
United States dollar

 
20 2 1 breakdown costs individual fuel type Table 9 cost column accept text use numbers
Mobile combustion fuels
Cost
Currency
Gasoline / petrol 80515069 United States dollar

 
Stationary combustion fuels
Cost
Currency
Bagasse 205174 United States dollar
Total Coal 5648601 United States dollar
Heavy Fuel Oil 7340479 United States dollar
Light Fuel Oil 19155770 United States dollar
Natural gas 89332418 United States dollar
Propane 128647 United States dollar

 
Energy fuel inputsThe following questions designed establish company’ s requirements energy fuel (inputs) note MWh preferred unit answers helps comparability analysis usually associated electricity equally used represent energy content fuels (see CDP2009 Reporting Guidance information conversions MWh) Purchased energy input20 3 company’ s total consumption purchased energy MWh use numbers
1815104 MWh

 
Purchased self produced fuel input20 4 company’ s total consumption MWh fuels stationary combustion includes purchased fuels biomass self produced fuels relevant use numbers
3276962 MWh

 
answering question used Higher Heating Values (also known Gross Calorific Values) Lower Heating Values (also known Net Calorific Values) state used calculating answers
Question included original survey section

 
20 4 1 break total consumption fuels reported answer question 20 4 individual fuel type MWh Table 10 use numbers
Stationary combustion fuels
MWh
Bagasse 13368
Total Coal 441984
Heavy Fuel Oil 170814
Light Fuel Oil 293491
Natural gas 2355611
Propane 1694

 
Energy outputIn question ask information energy MWh generated company fuel uses Comparing energy contained fuel combustion (question 20 4) energy available use combustion indication efficiency combustion processes taking industry sector account 20 5 total energy generated MWh fuels reported question 20 4 use numbers
0 MWh

 
20 6 total MWh renewable energy excluding biomass self generated company use numbers
951 MWh

 
Energy exportsThis question companies export energy surplus requirements example company use electricity combined heat power plant export heat organisation 20 7 percentage energy reported response question 20 5 exported/sold company grid parties use numbers
0 %

 
20 8 percentage renewable energy reported response question 20 6 exported/sold company grid parties use numbers
3 %

 
information
Information provided section does include global offices total cost use commodities thought insignificant reported Question 20 5 Pfizer does currently track energy generated stationary combustion fuels corporate level number facilities measure energy generated combustion fuels means track trend efficiency conversion processes specific pieces equipment Question 20 7 Sandwich facility United Kingdom exported 13 500 MWh onsite generated electricity 2008 Question 20 8 951 MWh energy generated 2008 renewable sources 27 MWh 2 8% (~3%) exported sold grid parties

 
21 EU Emissions Trading Scheme (CDP6 Q2(g)(i) – New wording CDP 2009)
Electric utilities report allowances emissions using table question EU5 21 1 Does company operate ownership facilities covered EU Emissions Trading Scheme (EU ETS)
Yes (Please answer the following questions - 21.2 to 21.4) 

 
details 21 2 allowances allocated free year Phase II facilities operate (Even wholly facilities number allowances) Table 11 use numbers
2008
2009
2010
2011
2012
Free allowances metric tonnes CO2 133642 116810 116810 116810 116180

 
21 3 total allowances purchased national auctioning processes period 1 January 2008 31 December 2008 facilities operate (Even wholly facilities total allowances purchased auctions facilities period) Total allowances purchased auction
0

 
21 4 total CO2 emissions 1 January 2008 31 December 2008 facilities operate (Even wholly facilities total emissions period )Total emissions metric tonnes
120869

 
information
Question 21 1 Pfizer owns operates facilities covered EU ETS

 
22 Emissions Trading (CDP6 Q2(g)(ii) New wording CDP 2009)
Electric utilities read EU6 answering questions
22 1 provide details emissions trading schemes EU ETS company participates likely participate years
We only participate in the EU ETS. (Please go to question 22.2) 

 
22 2 overall strategy complying schemes required elected participate including EU ETS
Pfizer expects regulated Carbon Reduction Commitment regulation United Kingdom time period comply regulation required

 
information

 
22 Carbon credits
22 3 purchased project based carbon credits
No. (Please go to question 22.5) 

 
indicate credits meet following commitments

 
22 4 Provide details including type unit volume vintage purchased standard/scheme credits verified issued retired (where applicable)

 
22 5 involved origination project based carbon credits
Yes. (Please answer the following question) 

 
22 6 provide details including • role project(s) • locations technologies involved • standard/scheme projects being/have developed • emissions reductions validated verified • annual volumes generated/projected carbon credits • Retirement method used compliance offsetting
SUMMARY Pfizer generated Clean Development Mechanism credits facility India retrofit boiler used residual fuel oil boiler uses bagasse project involved sale 12 200 metric tons CO2 eq verified credits 2008 owner operator facility facility located Thane India involved retrofitting boiler used residual fuel oil boiler uses bagasse fuel project registered Clean Development Mechanism project emissions reduction verified annual volume credits 12 200 metric tons CO2 eqRetirement method (if used compliance offsetting) applicable event

 
22 7 involved trading allowances EU ETS and/or project based carbon credits separate business activity direct support business activity investment fund management provision offsetting services
No. (Please go to question 23) 

 
22 8 provide details role performed

 
information

 
Performance
23 Reduction plans & goals (CDP6 Q3(a))
23 1 Does company GHG emissions and/or energy reduction plan place
Yes. (Please go to question 23.3) 

 
23 2 explain aid automated analysis responses select response options using text box just use text box provided options appropriate

 
menu options appropriate answer question using text box

 
Goal setting23 3 emissions and/or energy reduction target(s)
Yes. (Please answer the following questions) 

 
23 4 baseline year target(s)
baseline year second generation public goal reduce GHG emissions 2007

 
23 5 emissions and/or energy reduction target(s)
(1) published second generation GHG reduction goal reduce absolute GHG emissions 20% 2012 baseline year 2007 (2) public goal obtain 35% electricity clean energy sources 2010

 
23 6 sources activities target(s) applies
GHG reduction goal applies worldwide Pfizer operations operational control clean energy goal applies worldwide Pfizer operations

 
23 7 period/timescale does target(s) extend
GHG reduction goal baseline year 2007 goal period 2008 2012 clean energy goal goal end point December 31 2010

 
information

 
23 GHG emissions energy reduction activities
23 8 activities undertaking planning undertake reduce emissions/energy use
installing cogeneration units facilities implementing energy efficiency projects facilities striving reduce energy consumption engineering projects colleague awareness programs pursuing use renewable energy site installation renewable technologies facilities Connecticut Ireland

 
information

 
23 Goal evaluation
23 9 benchmarks key performance indicators use assess progress emissions/energy reduction goals set
monitor goal progress goals annual basis addition set annual internal energy efficiency goals business units include GHG reduction targets global fleet operations

 
information

 
23 Goal achievement
23 10 emissions reductions energy savings associated cost savings achieved date result plan and/or activities described state methodology data sources used calculating reductions savings
Pfizer exceeded generation public GHG reduction goal 2008 demonstrating 43% reduction GHG emissions million dollars revenue 2000 2007 goal achieve 35% reduction GHG emissions million dollars revenue follow WRI GHG Accounting Protocol track report emissions goal end 2008 Pfizer obtained 17 4 percent total electricity needs clean energy sources 2010 project 21 3 percent electricity clean energy sources 2015 project 30 19 percent Pfizer’ s electricity obtained clean energy sources including cogeneration solar installations clean sources addition Pfizer pursuing certain clean energy projects facilities relinquish rights renewable energy credits (“ RECs” ) generated project order make projects financially viable intent Pfizer’ s Clean Energy Goal promote development advancement clean energy technology believe supported actively pursuing renewable clean energy projects installing sites track projects separately Clean Energy Goal challenging goal attain proud 2010 projected obtain approximately 21 3 percent electricity clean energy sources shortfall originally stated goal number factors including closure certain plants cogeneration technology financial viability current clean energy technologies fully achieve goal 35% electricity usage come clean energy sources Pfizer remains committed development implementation clean energy technology makes good business environmental sense

 
23 11 investment required achieve emissions reductions energy savings targets carry activities listed response question 23 8 period investment Table 13 “ Investment number” column accept text use numbers
Emission reduction target/energy saving target or activity
Investment number
Investment currency
Timescale
Investments combined heat power (CHP cogeneration) systems 30000000 United States dollar 2008 2009 ($30M)
Investments annually energy efficiency upgrades energy conservation efforts 13500000 United States dollar Average annual basis ($12 15M)

 
information
Comment 2002 2008 Pfizer realized cumulative cost savings $125 million result global conservation efficiency efforts

 
23 Goal planning & investment
Electric utilities read table question EU3 giving details forecasted emissions
23 12 investment required achieve future targets set reduction plan carry activities listed response question 23 8 period expect payback investment Table 14 “ Number” column accept text use numbers
Plan or action
Investment number
Investment currency
Payback
Continued investments $12M $15M annually energy efficiency upgrades energy conservation efforts 13500000 United States dollar Comment Section

 
23 13 estimate company’ s future Scope 1 Scope 2 emissions years main territories regions operate provide qualitative explanation expected changes impact future GHG emissions possible use table 15 structure answer question alternatively use text box
January 2009 Pfizer Wyeth announced entered definitive merger agreement Pfizer acquire Wyeth cash stock transaction anticipated completion acquisition Wyeth perform baseline adjustment GHG data accordance GHG Inventory Management Plan approved USEPA’ s Climate Leaders Program time known extent carbon footprint acquired adjustments needed result

 
Scope 1 forecasted emissions Table 15 following units

 
Scope 2 forecasted emissions Table 15 following units

 
Table 15 “ Scope” columns accept text use numbers Type territory region giving data press “ Add Territory/Region” giving global figure instead separate figures regions territories write “ global” box labelled “ Enter territory region” Click sample table
Future reporting years:
End date for year end DD/MM/YYYY
Emission forecasts
Scope 1
Scope 2
Scope 1
Scope 2
Scope 1
Scope 2
Scope 1
Scope 2
Scope 1
Scope 2

 
23 14 estimate company’ s future energy use years main territories regions operate provide qualitative explanation expected changes impact future GHG emissions possible use table 16 structure answer question alternatively use text box
indicated response Question 23 13 acquisition Wyeth likely material affect GHG footprint energy usage

 
Table 16 use numbers Type territory region giving data description data giving e g electricity consumption press “ Add Row” giving global figure instead separate figures regions territories use word “ global” table accept different types units e g units volume mass Click sample table
Future reporting years:
End date for year end DD/MM/YYYY
Energy use estimates for territory/region
Number
Units
Number
Units
Number
Units
Number
Units
Number
Units

 
23 15 explain methodology used estimations assumptions
responses (23 12 23 14) goal planning questions general based preliminary knowledge Wyeth’ s energy climate change efforts publicly available information

 
information
Question 23 12 dedicated budget allocated implement efficiency improvements GHG reductions level investment years expected similar committed years Level investment depend overall return investment achieved program projects presented implementation

 
24 Planning (CDP6 Q3(c))
24 1 factor cost future emissions capital expenditures impact estimated costs investment decisions
value avoided GHG emissions treated sensitivity business case analysis conducted capital investment

 
information

 
Governance
25 Responsibility (CDP6 Q4(a))
25 1 Does Board Committee executive body overall responsibility climate change
Yes. (Please answer question 25.3 and 25.4) 

 
25 2 state overall responsibility climate change managed indicate highest level company responsibility climate change
Climate change strategy currently managed leader partnership Risk Management Global Operations Global Engineering EHS Legal Members Pfizer’ s Executive Leadership Team overall responsibility climate change direction Board Directors Audit Committee charged policy risk decisions Corporate Governance Committee corporate responsibility reputation governance framework

 
25 3 Board Committee executive body overall responsibility climate change
Audit Committee Pfizer’ s Chief Compliance Officer chairman Company’ s EHS Steering Team (senior leaders major business operating units) responsible informing Audit Committee Board key compliance significant risk Pfizer Audit Committee charged discussing Company policies respect risk assessment/management reviewing contingent liabilities material understanding major legislative regulatory developments materially impact Company’ s contingent liabilities risks extent climate change risks liabilities legislative/regulatory developments likely materially impact Company’ s contingent liabilities risks overseen Audit Committee Corporate Governance Committee Similarly Pfizer’ s Chief Governance Officer reports Corporate Governance Committee Board Directors Responsibilities Corporate Governance Committee include maintaining informed status Company issues related corporate social responsibility participation visibility global corporate citizen emerging issues potentially affecting reputation pharmaceutical industry Company extent changing climate global issue increasing concern implementation climate change strategy impact reputation issues overseen Corporate Governance Committee

 
25 4 mechanism Board executive body reviews company’ s progress status regarding climate change
Senior EHS leaders meet EHS Steering Team periodic basis include progress climate change energy activities Senior EHS leaders meet Pfizer’ s Executive Leadership Team comprised Senior Leaders organization needed basis review key EHS initiatives including climate change strategy risk opportunity performance Corporate Governance Committee Board Directors meet times annually Audit Committee chartered meet times year

 
information

 
26 Individual Performance (CDP6 Q4(b))
26 1 provide incentives individual management climate change issues including attainment GHG targets
Yes. (Please go to question 26.2)  

 
26 2 incentives linked monetary rewards
Energy efficiency improvement objectives set annual basis site energy teams objectives incorporated individual performance management plans key colleagues sites carbon reduction goals individual performance objectives key colleagues Compensation levels (e g salary increases bonuses) impacted degree goal achievement key colleagues

 
26 3 entitled benefit incentives
range individuals performance plans include related energy climate change objectives include • Facility energy champions• Global facility engineering staff • Global facility EH& S management • Utility managers sites• Facility leaders

 
information

 
27 Communications (CDP6 Q4(c))
27 1 publish information risks opportunities presented company climate change details emissions plans reduce emissions
Yes Pfizer publishes information risks opportunities presented company climate change includes details emissions plans reduce

 
indicate following apply provide details and/or link documents copy relevant excerpt 27 2 company’ s Annual Report mainstream filings
No 

 
27 3 Voluntary communications (other CDP) Corporate Social Responsibility reporting
Yes 
transparent climate change risks opportunities performance public disclosures CDP outlined Corporate Responsibility Report biennial publicationhttp //www pfizer com/responsibility/values_commitments/corporate_responsibility_report jsphttp //media pfizer com/files/corporate_citizenship/cr_report_2007 pdfUN Global Compact – Communications Progress 10 Principles CEO Mandate Caring Climate Business Leadership Platformhttp //www unglobalcompact org/COP/notable_cops htmlhttp //www unglobalcompact org/COP/notable_cops html detail=Pfizer%2C+Inc EPA Climate Leaders – GHG Goal Setting Goal Endorsement GHG Inventory Management Plan GHG Emissions Accountinghttp //www epa gov/stateply/partners/partners/pfizerinc htmlSocially Responsible Investor (SRI) GroupsQuestionnaires Reports (e g EIRIS Ceres SiRi Innovest)Individual Requests (e g Walden Asset Management)External Website – updated Sept 08www pfizer com/responsibility http //www pfizer com/responsibility/ehs/climate_change_and_energy jspSpeaking Engagements Interviews – e g Harvard Business Review (3Q09 publication) Pharmaceutical Technology Journalhttp //www ptemag com/pharmtecheurope/Manufacturing+and+Processing/Pharma going greener New Year/ArticleStandard/Article/detail/483080Our Colleagues EHS Ambassadors – Ensuring knowledge program equipping awareness tools

 
information
Question 27 2 debate certain stakeholders additional SEC guidance appropriate climate change matters current SEC rules require disclosure climate change risks liabilities material company Pfizer carefully evaluated climate change risks liabilities determined time material Company warrant disclosure SEC filings

 
28 Public Policy (CDP6 Q4(d))
28 1 engage policymakers possible responses climate change including taxation regulation carbon trading
No 

 
information
Pfizer determined active engagement policymakers critical advancement programs time focusing climate change efforts areas involvement voluntary activities reduce GHG emissions Pfizer hopes build knowledge base adapting mandatory programs reduce compliance costs going forward strengthen position proactive measures rewarded penalized mandatory GHG legislation comes play key aspect ensuring proactive measures rewarded establishment common GHG emissions reporting provide uniform transparent registry verify early actions taken reduce GHGs Pfizer reviewed analysed USEPA’ s recent proposed GHG Reporting Rule generally supportive initiative USEPA does directly address issue verifying early action decreases emissions evident multiple years reporting proposed EPA approach applied early action credit future legislation regulation GHG emissions Pfizer signatory Global Compact Business Leaders’ “ Caring Climate Business Leadership Platform” 2007 confirming belief climate change requires urgent extensive action governments business citizens avoid risk damage global prosperity security addition Pfizer participant strategic influential climate change partnerships proactively manage climate change issues Currently Pfizer member Environmental Protection Agency’ s Climate Leaders industry agency partnership focused developing long term climate change strategies Labs21 voluntary partnership program dedicated improving environmental performance laboratories WRI’ s Climate Northeast partnership northeast mid Atlantic based companies seeking develop climate change management strategies information sharing clean energy investment Business Roundtable’ s Climate RESOLVE encourages industries voluntary actions reduce GHG emissions United State’ s GHG intensity Pfizer participating Energy Security Innovation Sustainability (ESIS) Initiative sponsored Council Competitiveness (COC) mission ESIS Initiative enhance U S competitiveness energy security shaping public private action agenda drive private sector demand sustainable energy solutions support creation new industries markets jobs 2009 COC released “ Prioritize 100 Day Energy Action Plan 44th President United States” Council issue comprehensive set recommendations addressing need public private sector action National Energy Summit September 2009 Pfizer longstanding member Council active Advisor ESIS initiative Pfizer actively tracking development regulation GHG emissions domestic international levels believes mandatory reductions GHGs necessary tackle climate change Pfizer keeps colleagues engineering corporate site environmental programs apprised climate change energy legislative developments regulations impact Pfizer’ s operations offer opportunities advance Energy Climate Change program

 
We have upgraded our website login. If you have registered to view CDP responses before December 23, please re-register and we will issue new login details.
  Join the CDP LinkedIn group Follow @cdp on Twitter          Subscribe to receive our monthly newsletter
  Connect with us          Newsletter
   
 
 
  © 2014 CARBON DISCLOSURE PROJECT, Registered Charity no. 1122330.
A company limited by guarantee registered in England no. 05013650